Mindray (300760) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Jul, 2025Executive summary
2024FY revenue was 36.7 billion RMB, up 5.1% year-over-year, with net profit at 11.7 billion RMB, up 0.7%.
Net operating cash flow for 2024FY grew 12.4% to 12.4 billion RMB.
Q1 2025 revenue was 8.24 billion RMB, down 12.12% year-over-year; net profit was 2.63 billion RMB, down 16.81%.
International business in Q1 2025 grew nearly 5% year-over-year, with a two-year CAGR over 15%; international revenue share rose to 47%.
Domestic business in Q1 2025 declined over 20% year-over-year but increased more than 50% sequentially from Q4 2024.
Financial highlights
Gross margin for 2024FY was 63.1%, down 1.07 percentage points year-over-year.
Net margin for 2024FY was 31.77%, down 1.38 percentage points year-over-year.
Total assets at year-end 2024 were 56.6 billion RMB, up 18.2% year-over-year; at Q1 2025, assets reached 58.36 billion RMB, up 3.04% from year-end.
Operating cash flow in Q1 2025 was 1.49 billion RMB, down 47.83% year-over-year.
Basic and diluted EPS in Q1 2025 were RMB 2.1698, down over 16% year-over-year.
Outlook and guidance
Revenue in 2025 is expected to follow a pattern of a stronger second half, with a major growth turning point anticipated from Q3.
International business is expected to maintain rapid growth, especially in developing countries.
Domestic business is anticipated to rebound from Q3 2025 as equipment upgrades accelerate.
Latest events from Mindray
- Q3 revenue rebounded with international growth, but YTD net profit declined sharply.300760
Q3 202530 Oct 2025 - H1 2025 revenue and profit declined sharply, but international growth and digital transformation continue.300760
H1 202528 Aug 2025 - Double-digit profit and revenue growth, strong IVD, cardiovascular entry, high dividend.300760
H1 202423 Jul 2025 - Revenue and profit rose 8% year-over-year, led by strong international growth.300760
Q3 202423 Jul 2025 - AI-powered, multi-disciplinary solutions drive efficiency and global expansion in healthcare.300760
43rd Annual J.P. Morgan Healthcare Conference Presentation23 Jul 2025 - 2024FY saw modest growth and robust international expansion, with recovery expected in late 2025.300760
H2 202423 Jul 2025